Over the past six months, Phibro Animal Health’s shares (currently trading at $36.72) have posted a disappointing 18.5% loss, well below the S&P 500’s 11.5% gain. This may have investors wondering how to approach the situation.
Is now the time to buy Phibro Animal Health, or should you be careful about including it in your portfolio? Get the full breakdown from our expert analysts, it’s free.
Why Is Phibro Animal Health Not Exciting?
Even though the stock has become cheaper, we don't have much confidence in Phibro Animal Health. Here are three reasons we avoid PAHC and a stock we'd rather own.
1. Fewer Distribution Channels Limit its Ceiling
Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.
With just $1.5 billion in revenue over the past 12 months, Phibro Animal Health is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive.
2. Projected Revenue Growth Is Slim
Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite.
Over the next 12 months, sell-side analysts expect Phibro Animal Health’s revenue to rise by 2%, a deceleration versus its 13.4% annualized growth for the past five years. This projection doesn't excite us and suggests its products and services will face some demand challenges.
3. Breakeven Free Cash Flow Limits Reinvestment Potential
Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.
Phibro Animal Health broke even from a free cash flow perspective over the last five years, giving the company limited opportunities to return capital to shareholders.
Final Judgment
Phibro Animal Health isn’t a terrible business, but it doesn’t pass our quality test. Following the recent decline, the stock trades at 10.9× forward P/E (or $36.72 per share). While this valuation is fair, the upside isn’t great compared to the potential downside. We're fairly confident there are better stocks to buy right now. Let us point you toward a fast-growing restaurant franchise with an A+ ranch dressing sauce.
Stocks We Would Buy Instead of Phibro Animal Health
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
